Avanir Names Well-Known CRO and MedTech Industry Leader Jason Monteleone as New President and CEO

BILTHOVEN, The Netherlands & BOSTON- Avanir , a global contract research organization (CRO) providing product development, market access and clinical contract research services in the medical technology field, announced the appointment of Jason Monteleone as its new President and CEO , effective September 2, 2024. Monteleone succeeds Sapna Hornyak, who has served as President and CEO since 2019. Under Hornyak’s leadership, Avanir has built a strong, integrated global medtech platform. Jason will further strengthen Avanir’s position as a leading medtech CRO by driving growth strategies, deeper therapeutic expertise and innovation.

Monteleone has over 25 years of experience in the CRO, medical device and life sciences sectors and has deep expertise in driving growth, innovation and operational excellence. From 2017 to 2021, Monteleone served as CEO of Clinicace, a mid-market global CRO, where he grew profits by 65% prior to its acquisition by dMed in April 2021. He also served as CFO of Theorem Clinical Research, a mid-market global CRO focused on pharmaceutical and medical device research, where he doubled profits and employee numbers prior to its acquisition by Chiltern International in September 2015. Most recently, Monteleone served as President of Ancillare, a global company providing ancillary supplies and equipment for clinical trials.

Additionally, Monteleone serves as a board member and audit chair for the Drug Information Association (DIA), a global life sciences multidisciplinary membership organization that fosters collaboration in drug, medical device and diagnostic development for a healthier world. Monteleone founded Pivotal Financial Consulting, advising investors and companies in the clinical research space on acquisitions, growth strategies and innovation. Monteleone also has experience with VIASYS Healthcare, a publicly traded medical device company, where he served as Director of Finance for the company prior to its acquisition by Cardinal Health and its integration into CareFusion.

“I am honored to join Avanir and lead the company’s incredible team at such an exciting time in our industry,” said Monteleone. “Avanir partners with some of the world’s most innovative companies across a variety of therapeutic areas, including cardiovascular, neurology, orthopedics, aesthetics, to name a few. It is a great privilege to help our customers develop products that change the lives of their patients. That is what we are passionate about and what drives us to constantly innovate, collaborate and strive for excellence in every project.”

Todd Pope , Chairman of Avanir’s Board of Directors , said, ” I look forward to working closely with Jason as he leads Avanir to continue to positively impact our customers, employees and the medical technology community. As we continue to position Avanir at the forefront of innovation and operational excellence, the management team and board are very excited about its future.”

Edouard Pilote , Partner and Co-Head of Astorg Mid-Cap, Avanir’s largest shareholder , said, “We are excited to welcome Jason as Avanir’s new CEO. Jason’s strong track record of driving growth and operational excellence, combined with his extensive experience scaling businesses, makes him the ideal leader for Avanir’s next phase of growth. With his deep expertise in the CRO and medical technology industries, Jason will innovate and deliver unique solutions to our customers. We look forward to seeing Avanir create long-term value for our stakeholders under his leadership.”

About Avanir

Avanir is a leading, full-service contract research organization (CRO) with an international focus on managing clinical trials for medical devices, in vitro diagnostics (IVD), biopharmaceuticals and drug-device combination products. Avanir offers a uniform, customized approach to support products from early clinical trials through to post-marketing phases. Avanir is essential to the advancement of medical technology. Our vision is to be a trusted global partner in the evolution of medical technology from innovation to commercialization and improving the health and well-being of patients.

The official version of this press release is the original language version. The translated language versions are provided for the convenience of readers and have no legal effect. When using the translated version as a reference, please refer to the original language version, which is the only version that has legal effect.